Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.56 |
| ▸ | IL23R | Q5VWK5 | 16/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18505641 | 0.88 | IL23R (0.56) | OPRM1OPRD1OPRK1IL23R | |
| SCHEMBL29531748 | 0.85 | OPRD1 (0.53) | OPRM1OPRD1OPRK1IL23R | |
| SCHEMBL13209217 | 0.84 | IL23R (0.61) | IL23RSYK | |
| SCHEMBL13254722 | 0.83 | IL23R (0.54) | OPRM1OPRD1OPRK1IL23RSYK | |
| SCHEMBL30061253 | 0.80 | F2 (0.54) | OPRM1OPRD1OPRK1IL23R | |
| SCHEMBL30401130 | 0.79 | OPRD1 (0.51) | OPRM1OPRD1OPRK1IL23R | |
| SCHEMBL29826102 | 0.78 | KEAP1 (0.46) | OPRM1OPRD1OPRK1IL23R | |
| SCHEMBL31415958 | 0.78 | OPRD1 (0.50) | OPRM1OPRD1OPRK1IL23R | |
| SCHEMBL30724873 | 0.77 | TFPI (0.55) | OPRM1OPRD1OPRK1IL23R | |
| SCHEMBL29733394 | 0.77 | OPRD1 (0.51) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274436-A1 | USE OF ANILINE IN THE RADIOSTABILIZATION OF OXIME LIGATION | GE HEALTHCARE LIMITED (GB) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274436-A1 | USE OF ANILINE IN THE RADIOSTABILIZATION OF OXIME LIGATION | INMT, LIG4, LIG3 | OPRM1 1366/4885OPRD1 1730/4885OPRK1 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.